HemaSphere
(Jun 2022)
PB2081: TREATMENT PERSISTENCE AND ADHERENCE TO IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA: A GERMAN CLAIMS DATA ANALYSIS
- C. Buske,
- G. Hess,
- N. Bahar,
- K. Yang,
- B. Tang,
- A. Imhof,
- K. Vinz,
- E. Herweijer,
- M. Herold
Affiliations
- C. Buske
- 1 Institut für Experimentelle Tumorforschung, Universitätsklinikum Ulm, Ulm
- G. Hess
- 2 III. Med. Klinik | UCT Mainz | Universitätsmedizin Mainz, Mainz, Germany
- N. Bahar
- 3 BeiGene Switzerland GmbH, Basel, Switzerland
- K. Yang
- 4 BeiGene USA, Inc., San Mateo, United States of America
- B. Tang
- 4 BeiGene USA, Inc., San Mateo, United States of America
- A. Imhof
- 5 BeiGene Germany GmbH, München
- K. Vinz
- 5 BeiGene Germany GmbH, München
- E. Herweijer
- 6 Ingress-Health HWM GmbH, Wismar
- M. Herold
- 7 Helios Klinikum Erfurt, Erfurt, Germany
- DOI
-
https://doi.org/10.1097/01.HS9.0000851156.61481.73
- Journal volume & issue
-
Vol. 6
pp.
1952
– 1953
WeChat QR code